Loading
Life sciences · Journal article
Frontiers in Oncology · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer is the most common malignancy among women worldwide, and hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-low breast cancer poses significant challenges once resistance to endocrine therapy and CDK4/6 inhibitors develops. We present a 45-year-old female patient with HR+/HER2-low metastatic breast cancer who progressed on standard-of-care treatments. The combination of trastuzumab deruxtecan and fulvestrant demonstrated significant clinical efficacy and favorable tolerability, achieving a progression-free survival of 26 months with no grade 3 or higher adverse events observed. This case suggests that this combination may represent a promising therapeutic strategy for patients with advanced, treatment-refractory HR+/HER2-low breast cancer, offering a useful reference for clinical practice.